Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer (original) (raw)

• Clinical Oncology/Epidemiology
• Published: 01 July 1996

Clinical Oncology/Epidemiology

• AP Forrest na1,
• D Everington na1,
• CC McDonald na1,
• JA Dewar na1,
• RA Hawkins na1,
• RJ Prescott na1 &
• WD George na1 on behalf of
• The Scottish Cancer Trials Breast Group

British Journal of Cancer volume 74, pages 297–299 (1996)Cite this article

• 313 Accesses
• 3 Altmetric
• Metrics details

Abstract

In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of outcome in 342 patients at a median follow-up of 6 years suggests that a worthwhile gain in disease control from continuing adjuvant tamoxifen beyond 5 years is unlikely. [Hazard ratio for events (relapse or death without relapse) is 1.27, 95% CI = 0.87 - 1.85.] There is a suggestion that therapy for longer than 5 years may increase the risk of endometrial carcinoma (P = 0.064).

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 24 print issues and online access

$259.00 per year

only $10.79 per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

• Log in
• Learn about institutional subscriptions
• Read our FAQs
• Contact customer support

Similar content being viewed by others

Author information

Author notes

1. HJ Stewart, AP Forrest, D Everington, CC McDonald, JA Dewar, RA Hawkins, RJ Prescott and WD George: Present membership: Professor 0 Eremin FRCSE, A Hutcheon FRCPG and T Sarkar FRCR (Aberdeen); J Dewar FRCR and P Preece FRCS (Dundee); U Chetty FRCSE, RA Hawkins PhD, RCF Leonard FRCPE, RJ Prescott PhD and HJ Stewart FRCR (Edinburgh); Professor WD George FRCS (chairman), A Harnett FRCR, Professor S Kaye FRCP, RE Leake DPhil, Professor CS McArdle FRCS and DC Smith FRCS (Glasgow); PV Walsh FRCS (Inverness).

Authors and Affiliations

1. Scottish Cancer Trials Office, Medical School, University of Edinburgh, UK
   HJ Stewart

Authors

1. HJ Stewart
   You can also search for this author inPubMed Google Scholar
2. AP Forrest
   You can also search for this author inPubMed Google Scholar
3. D Everington
   You can also search for this author inPubMed Google Scholar
4. CC McDonald
   You can also search for this author inPubMed Google Scholar
5. JA Dewar
   You can also search for this author inPubMed Google Scholar
6. RA Hawkins
   You can also search for this author inPubMed Google Scholar
7. RJ Prescott
   You can also search for this author inPubMed Google Scholar
8. WD George
   You can also search for this author inPubMed Google Scholar

Consortia

The Scottish Cancer Trials Breast Group

Rights and permissions

About this article

Cite this article

Stewart, H., Forrest, A., Everington, D. et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer.Br J Cancer 74, 297–299 (1996). https://doi.org/10.1038/bjc.1996.356

Download citation

• Issue Date: 01 July 1996
• DOI: https://doi.org/10.1038/bjc.1996.356